Denosumab, a fully human monoclonal antibody against RANKL, has been used clinically for treatment of osteoporosis and bone erosion associated with multiple myeloma and bone metastasis from tumors [6,7]. The gene discussed is TNFSF11; the disease is AL amyloidosis.